Karuna Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 1.39
Dividend & YieldN/A$ (N/A)
Beta 1.14
Market capitalization 7.67B
Operating cash flow -156.25M
ESG Scores unknown

Company description

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -529k 278k 318k 1.07M
Total Cashflows From Investing Activities -5.12M -174.34M -89.65M -22.69M
Net Borrowings 11.7M 3.13M
Total Cash From Financing Activities 27.58M 405.28M 3.66M 277.57M
Change To Operating Activities -1.33M -115k -15.9M 11.52M
Issuance Of Stock 330.14M 330.14M 4.1M 277.86M
Net Income -17.51M -43.96M -68.55M -143.81M
Change In Cash 7.08M 200.03M -155.85M 154.01M
Effect Of Exchange Rate
Total Cash From Operating Activities -15.38M -30.92M -69.86M -100.88M
Depreciation 6k 58k 145k 506k
Change To Account Receivables -1.75M -1.75M -1.75M -1.75M
Other Cashflows From Financing Activities -2.81M -2.81M -439k -283k
Change To Netincome 1.81M 11.87M 14.13M 31.58M
Capital Expenditures -132k -115k -419k -3.07M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 11.54M 24.54M 41.41M 128.2M
Income Before Tax -17.51M -43.96M -68.51M -143.8M
Net Income -17.51M -43.96M -68.55M -143.81M
Selling General Administrative 2.97M 20.87M 28.41M 52.36M
Gross Profit 36.96M
Ebit -14.51M -45.41M -69.82M -143.6M
Operating Income -14.51M -45.41M -69.82M -143.6M
Interest Expense -2.58M -945k
Income Tax Expense 43k 6k
Total Revenue 36.96M
Cost Of Revenue
Total Other Income ExpenseNet -3M 1.45M 1.3M -200k
Net Income From Continuing Ops -17.51M -43.96M -68.55M -143.81M
Net Income Applicable To Common Shares -17.51M -43.96M -68.55M -143.81M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 3.81M 3.11M 8.69M 25.64M
Total Stockholder Equity -29.92M 389.92M 338.93M 502.03M
Other Current Liabilities 389k 58k
Total Assets 15.86M 393.02M 347.62M 527.67M
Common Stock 3k 3k 3k
Other Current Assets 1.69M 1.18M 20.15M 19.23M
Retained Earnings -31.55M -75.51M -144.07M -287.87M
Treasury Stock 5k 39k -497k
Cash 8.9M 208.93M 53.05M 206.95M
Total Current Liabilities 1.2M 2.96M 6.85M 20.21M
Other Stockholder Equity 5k 39k -497k
Property, Plant, and Equipment 138k 195k 2.87M 9.54M
Total Current Assets 15.6M 392.71M 344.6M 517.33M
Net Tangible Assets -29.92M 389.92M 338.93M 502.03M
Net Receivables 1.75M
Accounts Payable 269k 547k 865k 1.94M


Insider Transactions

Here are the insider transactions of stock shares related to Karuna Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
IGNELZI TROY ASale at price 225.85 per share.D2022-11-15Chief Financial Officer16.5k
IGNELZI TROY AConversion of Exercise of derivative security at price 9.20 per share.D2022-11-15Chief Financial Officer16.5k
MILLER ANDREW CRAIGConversion of Exercise of derivative security at price 2.92 - 7.27 per share.D2022-11-11Chief Operating Officer2k
MILLER ANDREW CRAIGSale at price 225.98 per share.D2022-11-10Chief Operating Officer15k
BRANNAN STEPHEN K M.D.Sale at price 216.00 per share.D2022-11-09Officer5k
BRANNAN STEPHEN K M.D.Conversion of Exercise of derivative security at price 9.20 per share.D2022-11-09Officer5k
MILLER ANDREW CRAIGConversion of Exercise of derivative security at price 2.92 per share.D2022-11-03Chief Operating Officer2k
MILLER ANDREW CRAIGSale at price 225.08 per share.D2022-11-01Chief Operating Officer15k
OLSON LAURIE JEANNESale at price 205.63 per share.D2022-10-11Director1k
OLSON LAURIE JEANNEConversion of Exercise of derivative security at price 84.86 per share.D2022-10-11Director1k
BRANNAN STEPHEN K M.D.Sale at price 207.51 per share.D2022-10-10Officer5k
BRANNAN STEPHEN K M.D.Conversion of Exercise of derivative security at price 9.20 per share.D2022-10-10Officer5k
IGNELZI TROY ASale at price 227.05 - 233.20 per share.D2022-10-04Chief Financial Officer15k
BRANNAN STEPHEN K M.D.Sale at price 243.46 per share.D2022-09-09Officer5k
BRANNAN STEPHEN K M.D.Conversion of Exercise of derivative security at price 7.27 per share.D2022-09-09Officer5k
OLSON LAURIE JEANNESale at price 267.59 per share.D2022-08-15Director1k
OLSON LAURIE JEANNEConversion of Exercise of derivative security at price 84.86 per share.D2022-08-15Director1k
OLSON LAURIE JEANNESale at price 267.59 per share.D2022-08-15Director1k
OLSON LAURIE JEANNEConversion of Exercise of derivative security at price 84.86 per share.D2022-08-15Director1k
IGNELZI TROY ASale at price 227.83 per share.D2022-08-09Chief Financial Officer16.5k
IGNELZI TROY AConversion of Exercise of derivative security at price 9.20 per share.D2022-08-09Chief Financial Officer16.5k
BRANNAN STEPHEN K M.D.Sale at price 228.05 - 228.13 per share.D2022-08-09Officer25k
BRANNAN STEPHEN K M.D.Conversion of Exercise of derivative security at price 7.27 - 9.20 per share.D2022-08-09Officer25k
HEALY JAMES IConversion of Exercise of derivative security at price 16.00 per share.D2022-08-05Director32.5k
BRANNAN STEPHEN K M.D.Sale at price 133.29 per share.D2022-07-11Officer15k
BRANNAN STEPHEN K M.D.Conversion of Exercise of derivative security at price 9.20 per share.D2022-07-11Officer15k
HEALY JAMES IPurchase at price 121.99 - 125.00 per share.I2022-06-30Director120k
BRANNAN STEPHEN K M.D.Sale at price 110.90 per share.D2022-06-09Officer5k
BRANNAN STEPHEN K M.D.Conversion of Exercise of derivative security at price 9.20 per share.D2022-06-09Officer5k
OLSON LAURIE JEANNESale at price 110.00 per share.D2022-05-27Director1k
OLSON LAURIE JEANNEConversion of Exercise of derivative security at price 84.86 per share.D2022-05-27Director1k
BRANNAN STEPHEN K M.D.Sale at price 104.10 per share.D2022-05-09Officer5k
BRANNAN STEPHEN K M.D.Conversion of Exercise of derivative security at price 9.20 per share.D2022-05-09Officer5k
IGNELZI TROY ASale at price 130.81 - 134.46 per share.D2022-04-21Chief Financial Officer4.24k
IGNELZI TROY AConversion of Exercise of derivative security at price 9.20 per share.D2022-04-21Chief Financial Officer4.24k
HEALY JAMES IPurchase at price 129.38 per share.I2022-04-01Director47
BRANNAN STEPHEN K M.D.Sale at price 128.45 per share.D2022-04-01Officer7.73k
BRANNAN STEPHEN K M.D.Conversion of Exercise of derivative security at price 5.45 - 7.27 per share.D2022-04-01Officer10.23k
BRANNAN STEPHEN K M.D.Sale at price 107.38 per share.D2022-03-01Officer7.73k
BRANNAN STEPHEN K M.D.Conversion of Exercise of derivative security at price 5.45 - 9.20 per share.D2022-03-01Officer10.23k
OLSON LAURIE JEANNESale at price 110.00 per share.D2022-02-15Director1k
OLSON LAURIE JEANNEConversion of Exercise of derivative security at price 84.86 per share.D2022-02-15Director1k
IGNELZI TROY ASale at price 111.14 per share.D2022-02-15Chief Financial Officer1.5k
IGNELZI TROY AConversion of Exercise of derivative security at price 9.20 per share.D2022-02-15Chief Financial Officer1.5k
PANDE ATULSale at price 110.80 per share.D2022-02-01Unknown2.5k
PANDE ATULConversion of Exercise of derivative security at price 16.00 per share.D2022-02-01Unknown2.5k
BRANNAN STEPHEN K M.D.Sale at price 110.05 per share.D2022-02-01Officer7.73k
BRANNAN STEPHEN K M.D.Conversion of Exercise of derivative security at price 5.45 - 7.27 per share.D2022-02-01Officer10.23k
PANDE ATULSale at price 130.44 per share.D2022-01-03Director2.5k
PANDE ATULConversion of Exercise of derivative security at price 16.00 per share.D2022-01-03Director2.5k
BRANNAN STEPHEN K M.D.Sale at price 130.79 per share.D2022-01-03Officer7.73k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Karuna Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Karuna Therapeutics Inc

Here is the result of two systematic investment strategies applied to Karuna Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Karuna Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Karuna Therapeutics Inc:

Karuna Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 198.5% on the backtest period.

Performance at glance

Performance

198.5 %

Latent gain

2377.28 $

Invested capital

1197.61 $

Annualized return

80.69 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Karuna Therapeutics Inc

This is the result of two momentum investment strategies applied to Karuna Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Karuna Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Karuna Therapeutics Inc:

Karuna Therapeutics Inc momentum entries
  • The first momentum investment strategy would give 226.47% of return on Karuna Therapeutics Inc. That represents 5714.49$ of latent gain with 2523.3$ of employed capital.
  • The second momentum investment strategy would give 63.07% of return on Karuna Therapeutics Inc. That represents 1623.08$ of latent gain with 2573.53$ of employed capital.
Performance at glance (1Q Momentum)

Performance

226.47 %

Latent gain

5714.49 $

Invested capital

2523.3 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

63.07 %

Latent gain

1623.08 $

Invested capital

2573.53 $

Annualized return

31.85 %

Momentum equity curve on Karuna Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Karuna Therapeutics Inc:

Karuna Therapeutics Inc momentum equity

Note: the dividends potentially given by Karuna Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Karuna Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Karuna Therapeutics Inc since the beginning:

Karuna Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Karuna Therapeutics Inc

Buy the dip entry openings on Karuna Therapeutics Inc

Karuna Therapeutics Inc

The performance achieved by the robo-advisor on Karuna Therapeutics Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Karuna Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Karuna Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Karuna Therapeutics Inc

The following chart shows the result of the investment strategy applied to Karuna Therapeutics Inc:

Karuna Therapeutics Inc

Note: the dividends potentially given by Karuna Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Karuna Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Karuna Therapeutics Inc:

Karuna Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Karuna Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Karuna Therapeutics Inc.

Equity curve comparison on Karuna Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Karuna Therapeutics Inc investment strategy comparison

Employed capital comparison on Karuna Therapeutics Inc

Karuna Therapeutics Inc investment comparison

Performance comparison on Karuna Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 198.5% 2377.28$ 1197.61$ 80.69%
Momentum 1 quarter 226.47% 5714.49$ 2523.3$ 102.01%
Momentum 2 quarters 63.07% 1623.08$ 2573.53$ 31.85%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

80.69 %

Momentum 1Q

31.85 %

Momentum 2Q

31.85 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Karuna Therapeutics Inc:

Positive correlations

Most correlated stocks this year

  • Karuna Therapeutics Inc

  • Most correlated stocks last 3 months

  • BAR PACIFIC
  • AIR LIQUIDE
  • AXWAY SOFTWARE
  • Karuna Therapeutics Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • SAREUM HOLDINGS PLC ORD 0.025P

  • Note: The algorithm computes the probability of correlation between Karuna Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Karuna Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Karuna Therapeutics Inc
    Country United States
    City Boston
    Address 99 High Street
    Phone 857 449 2244
    Website www.karunatx.com
    FullTime employees 118
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker KRTX
    Market www.nasdaq.com

    Karuna Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown